Concepts (285)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Uterine Cervical Neoplasms | 49 | 2025 | 350 | 9.680 |
Why?
|
| Mass Screening | 20 | 2024 | 531 | 3.180 |
Why?
|
| Zambia | 34 | 2025 | 47 | 3.140 |
Why?
|
| Early Detection of Cancer | 19 | 2025 | 428 | 3.060 |
Why?
|
| Breast Neoplasms | 24 | 2025 | 1679 | 2.740 |
Why?
|
| Uterine Cervical Dysplasia | 10 | 2024 | 41 | 1.870 |
Why?
|
| Female | 84 | 2025 | 24018 | 1.450 |
Why?
|
| Papillomavirus Infections | 11 | 2024 | 363 | 1.350 |
Why?
|
| HIV Infections | 18 | 2025 | 2535 | 1.320 |
Why?
|
| Developing Countries | 9 | 2023 | 112 | 1.160 |
Why?
|
| Cryotherapy | 7 | 2025 | 11 | 1.140 |
Why?
|
| Humans | 90 | 2025 | 42163 | 1.130 |
Why?
|
| Community Health Planning | 4 | 2018 | 38 | 1.070 |
Why?
|
| Medical Oncology | 3 | 2024 | 46 | 1.010 |
Why?
|
| Adult | 40 | 2025 | 13458 | 0.980 |
Why?
|
| Middle Aged | 37 | 2025 | 11819 | 0.970 |
Why?
|
| Neoplasms | 8 | 2023 | 1341 | 0.900 |
Why?
|
| Ultrasonography, Mammary | 2 | 2020 | 8 | 0.860 |
Why?
|
| Gynecology | 1 | 2024 | 33 | 0.840 |
Why?
|
| Primary Health Care | 2 | 2024 | 362 | 0.810 |
Why?
|
| Africa South of the Sahara | 16 | 2025 | 51 | 0.800 |
Why?
|
| Endometrial Neoplasms | 1 | 2024 | 79 | 0.780 |
Why?
|
| Health Services Accessibility | 9 | 2024 | 680 | 0.740 |
Why?
|
| Prospective Studies | 14 | 2025 | 1574 | 0.700 |
Why?
|
| Image Interpretation, Computer-Assisted | 1 | 2020 | 57 | 0.670 |
Why?
|
| Papillomaviridae | 7 | 2024 | 136 | 0.650 |
Why?
|
| Health Promotion | 4 | 2019 | 691 | 0.640 |
Why?
|
| Algorithms | 2 | 2024 | 508 | 0.630 |
Why?
|
| Point-of-Care Systems | 2 | 2016 | 35 | 0.610 |
Why?
|
| Program Evaluation | 3 | 2015 | 358 | 0.580 |
Why?
|
| Breast Diseases | 1 | 2018 | 5 | 0.580 |
Why?
|
| Health Knowledge, Attitudes, Practice | 7 | 2018 | 959 | 0.570 |
Why?
|
| Delivery of Health Care | 7 | 2022 | 309 | 0.570 |
Why?
|
| Program Development | 3 | 2015 | 237 | 0.560 |
Why?
|
| Healthcare Disparities | 6 | 2024 | 573 | 0.560 |
Why?
|
| Rural Health Services | 1 | 2018 | 47 | 0.550 |
Why?
|
| Neoplasm Staging | 8 | 2024 | 366 | 0.550 |
Why?
|
| Vaginal Smears | 5 | 2011 | 62 | 0.530 |
Why?
|
| Acquired Immunodeficiency Syndrome | 3 | 2013 | 225 | 0.490 |
Why?
|
| Diagnostic Tests, Routine | 1 | 2016 | 51 | 0.490 |
Why?
|
| Acetic Acid | 4 | 2021 | 19 | 0.480 |
Why?
|
| Electrosurgery | 3 | 2024 | 3 | 0.460 |
Why?
|
| Condylomata Acuminata | 1 | 2013 | 6 | 0.430 |
Why?
|
| Referral and Consultation | 4 | 2024 | 141 | 0.420 |
Why?
|
| Incidence | 7 | 2024 | 1054 | 0.420 |
Why?
|
| Women's Health | 6 | 2016 | 158 | 0.410 |
Why?
|
| Genital Neoplasms, Female | 2 | 2025 | 17 | 0.410 |
Why?
|
| Anus Neoplasms | 1 | 2013 | 43 | 0.410 |
Why?
|
| Socioeconomic Factors | 7 | 2024 | 1221 | 0.390 |
Why?
|
| Telemedicine | 2 | 2020 | 215 | 0.380 |
Why?
|
| Sensitivity and Specificity | 5 | 2024 | 602 | 0.380 |
Why?
|
| United States | 9 | 2024 | 5072 | 0.370 |
Why?
|
| Preventive Health Services | 2 | 2012 | 65 | 0.370 |
Why?
|
| Poverty | 4 | 2022 | 395 | 0.370 |
Why?
|
| Health Resources | 1 | 2011 | 37 | 0.350 |
Why?
|
| Vagina | 2 | 2025 | 89 | 0.320 |
Why?
|
| Health Status Disparities | 2 | 2024 | 705 | 0.310 |
Why?
|
| Health Care Coalitions | 2 | 2006 | 11 | 0.310 |
Why?
|
| Attitude to Health | 3 | 2012 | 336 | 0.310 |
Why?
|
| Rural Population | 6 | 2024 | 352 | 0.310 |
Why?
|
| Peer Group | 1 | 2010 | 173 | 0.300 |
Why?
|
| Aged | 12 | 2025 | 7982 | 0.290 |
Why?
|
| Reproductive Health Services | 1 | 2008 | 14 | 0.290 |
Why?
|
| Patient Education as Topic | 1 | 2010 | 234 | 0.280 |
Why?
|
| Cervix Uteri | 3 | 2015 | 47 | 0.280 |
Why?
|
| Delivery of Health Care, Integrated | 1 | 2008 | 37 | 0.280 |
Why?
|
| Treatment Outcome | 5 | 2025 | 1586 | 0.280 |
Why?
|
| Cohort Studies | 9 | 2023 | 1729 | 0.280 |
Why?
|
| Computer Simulation | 2 | 2021 | 404 | 0.270 |
Why?
|
| Social Justice | 1 | 2007 | 64 | 0.260 |
Why?
|
| Prognosis | 4 | 2024 | 850 | 0.260 |
Why?
|
| Healthy People Programs | 1 | 2006 | 25 | 0.250 |
Why?
|
| Ovarian Neoplasms | 3 | 2005 | 406 | 0.250 |
Why?
|
| Cooperative Behavior | 3 | 2019 | 250 | 0.240 |
Why?
|
| Community Health Services | 1 | 2007 | 207 | 0.240 |
Why?
|
| Diathermy | 1 | 2025 | 1 | 0.240 |
Why?
|
| Survival Analysis | 5 | 2024 | 362 | 0.240 |
Why?
|
| Colposcopy | 2 | 2015 | 14 | 0.230 |
Why?
|
| Dairy Products | 1 | 2005 | 34 | 0.230 |
Why?
|
| Patient Care Team | 1 | 2025 | 57 | 0.230 |
Why?
|
| Reproduction | 1 | 2005 | 92 | 0.230 |
Why?
|
| HIV Seropositivity | 2 | 2018 | 196 | 0.220 |
Why?
|
| Clinical Competence | 2 | 2021 | 154 | 0.220 |
Why?
|
| Ablation Techniques | 1 | 2024 | 1 | 0.220 |
Why?
|
| ROC Curve | 1 | 2024 | 157 | 0.210 |
Why?
|
| Demography | 2 | 2015 | 195 | 0.210 |
Why?
|
| History, 20th Century | 1 | 2024 | 124 | 0.210 |
Why?
|
| Life Expectancy | 1 | 2024 | 69 | 0.210 |
Why?
|
| Artificial Intelligence | 1 | 2024 | 94 | 0.200 |
Why?
|
| Photography | 2 | 2015 | 48 | 0.200 |
Why?
|
| Radiotherapy | 1 | 2002 | 21 | 0.200 |
Why?
|
| Blood Transfusion | 1 | 2002 | 30 | 0.200 |
Why?
|
| Specimen Handling | 1 | 2003 | 61 | 0.190 |
Why?
|
| Cystadenocarcinoma, Papillary | 1 | 2002 | 3 | 0.190 |
Why?
|
| Income | 4 | 2022 | 160 | 0.190 |
Why?
|
| Oncogene Proteins, Viral | 1 | 2002 | 25 | 0.190 |
Why?
|
| Interleukin-10 | 1 | 2002 | 86 | 0.190 |
Why?
|
| Adolescent | 10 | 2025 | 5950 | 0.190 |
Why?
|
| Cystadenocarcinoma, Serous | 1 | 2002 | 44 | 0.180 |
Why?
|
| Shoulder | 1 | 2021 | 10 | 0.180 |
Why?
|
| Arm | 1 | 2021 | 28 | 0.180 |
Why?
|
| Predictive Value of Tests | 3 | 2016 | 438 | 0.180 |
Why?
|
| Dendritic Cells | 1 | 2002 | 130 | 0.180 |
Why?
|
| Child, Orphaned | 1 | 2021 | 3 | 0.180 |
Why?
|
| Uterine Neoplasms | 1 | 2002 | 51 | 0.170 |
Why?
|
| Democratic Republic of the Congo | 1 | 2020 | 6 | 0.170 |
Why?
|
| Biopsy, Fine-Needle | 1 | 2020 | 12 | 0.170 |
Why?
|
| Ultrasonography, Interventional | 1 | 2020 | 20 | 0.170 |
Why?
|
| Prevalence | 5 | 2015 | 1597 | 0.170 |
Why?
|
| Adenocarcinoma | 2 | 2006 | 287 | 0.170 |
Why?
|
| Receptor, erbB-2 | 1 | 2002 | 149 | 0.170 |
Why?
|
| Africa | 4 | 2022 | 81 | 0.170 |
Why?
|
| Immunotherapy | 1 | 2002 | 137 | 0.170 |
Why?
|
| Young Adult | 9 | 2025 | 4936 | 0.160 |
Why?
|
| Diagnosis, Differential | 1 | 2020 | 236 | 0.160 |
Why?
|
| Feasibility Studies | 1 | 2020 | 238 | 0.160 |
Why?
|
| Hyperthermia, Induced | 1 | 2019 | 27 | 0.160 |
Why?
|
| Male | 8 | 2024 | 22779 | 0.160 |
Why?
|
| Learning | 1 | 2021 | 155 | 0.160 |
Why?
|
| Breast | 1 | 2020 | 139 | 0.160 |
Why?
|
| Gynecologic Surgical Procedures | 1 | 2019 | 8 | 0.150 |
Why?
|
| Obesity | 1 | 2007 | 1131 | 0.150 |
Why?
|
| Diet | 1 | 2005 | 810 | 0.150 |
Why?
|
| Retrospective Studies | 3 | 2019 | 2485 | 0.150 |
Why?
|
| DNA-Binding Proteins | 1 | 2002 | 557 | 0.150 |
Why?
|
| HIV Seronegativity | 1 | 2018 | 41 | 0.150 |
Why?
|
| Human papillomavirus 16 | 2 | 2015 | 37 | 0.140 |
Why?
|
| Age Factors | 2 | 2025 | 1139 | 0.140 |
Why?
|
| Risk Assessment | 2 | 2015 | 845 | 0.140 |
Why?
|
| Biomedical Research | 1 | 2022 | 467 | 0.130 |
Why?
|
| Health Services Needs and Demand | 2 | 2015 | 154 | 0.130 |
Why?
|
| Lung Neoplasms | 1 | 2002 | 479 | 0.130 |
Why?
|
| Alabama | 3 | 2006 | 52 | 0.130 |
Why?
|
| Uterine Cervical Diseases | 1 | 2015 | 14 | 0.120 |
Why?
|
| Histocytochemistry | 1 | 2015 | 47 | 0.120 |
Why?
|
| Adenosine Triphosphatases | 1 | 2016 | 83 | 0.120 |
Why?
|
| Observer Variation | 1 | 2015 | 58 | 0.120 |
Why?
|
| Prostatic Neoplasms | 1 | 2005 | 1068 | 0.120 |
Why?
|
| Residence Characteristics | 1 | 2018 | 359 | 0.120 |
Why?
|
| Cross-Sectional Studies | 4 | 2016 | 3077 | 0.120 |
Why?
|
| Staining and Labeling | 1 | 2015 | 106 | 0.120 |
Why?
|
| Human papillomavirus 18 | 1 | 2015 | 6 | 0.120 |
Why?
|
| Follow-Up Studies | 3 | 2025 | 1051 | 0.120 |
Why?
|
| Molecular Diagnostic Techniques | 1 | 2015 | 25 | 0.110 |
Why?
|
| Mississippi | 2 | 2007 | 129 | 0.110 |
Why?
|
| Cost-Benefit Analysis | 3 | 2025 | 176 | 0.110 |
Why?
|
| Cytological Techniques | 1 | 2014 | 14 | 0.110 |
Why?
|
| Logistic Models | 2 | 2017 | 1001 | 0.110 |
Why?
|
| Papillomavirus Vaccines | 2 | 2015 | 168 | 0.110 |
Why?
|
| Proportional Hazards Models | 3 | 2025 | 512 | 0.110 |
Why?
|
| Topography, Medical | 1 | 2013 | 2 | 0.110 |
Why?
|
| South Africa | 3 | 2022 | 38 | 0.110 |
Why?
|
| Pregnancy | 3 | 2023 | 1737 | 0.110 |
Why?
|
| Cell Cycle Proteins | 1 | 2016 | 239 | 0.100 |
Why?
|
| Alphapapillomavirus | 1 | 2013 | 30 | 0.100 |
Why?
|
| Sex Education | 1 | 2013 | 36 | 0.100 |
Why?
|
| Probability | 1 | 2013 | 82 | 0.100 |
Why?
|
| HIV | 1 | 2013 | 100 | 0.100 |
Why?
|
| Social Class | 2 | 2016 | 286 | 0.100 |
Why?
|
| Fertility | 2 | 2023 | 63 | 0.100 |
Why?
|
| Genital Diseases, Female | 1 | 2012 | 38 | 0.090 |
Why?
|
| Survival Rate | 2 | 2020 | 353 | 0.090 |
Why?
|
| Metagenome | 1 | 2012 | 31 | 0.090 |
Why?
|
| Child | 4 | 2022 | 3381 | 0.090 |
Why?
|
| Multivariate Analysis | 1 | 2013 | 638 | 0.090 |
Why?
|
| Urban Population | 3 | 2024 | 364 | 0.090 |
Why?
|
| Killer Cells, Natural | 2 | 2002 | 99 | 0.090 |
Why?
|
| Patient Preference | 1 | 2012 | 55 | 0.090 |
Why?
|
| Health Plan Implementation | 1 | 2011 | 14 | 0.090 |
Why?
|
| Disease-Free Survival | 3 | 2006 | 116 | 0.090 |
Why?
|
| Medical Informatics | 1 | 2011 | 24 | 0.090 |
Why?
|
| Flow Cytometry | 2 | 2002 | 411 | 0.090 |
Why?
|
| Patient Participation | 1 | 2012 | 87 | 0.090 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2015 | 471 | 0.080 |
Why?
|
| Education | 1 | 2010 | 60 | 0.080 |
Why?
|
| Minority Groups | 2 | 2007 | 663 | 0.080 |
Why?
|
| Nurses | 1 | 2010 | 55 | 0.080 |
Why?
|
| Focus Groups | 2 | 2012 | 398 | 0.080 |
Why?
|
| Data Collection | 1 | 2010 | 210 | 0.080 |
Why?
|
| Beneficence | 1 | 2007 | 2 | 0.070 |
Why?
|
| Biopsy | 1 | 2008 | 176 | 0.070 |
Why?
|
| Personal Autonomy | 1 | 2007 | 21 | 0.070 |
Why?
|
| Risk Factors | 3 | 2021 | 3942 | 0.070 |
Why?
|
| Community-Institutional Relations | 2 | 2006 | 208 | 0.070 |
Why?
|
| Quality of Life | 2 | 2016 | 599 | 0.070 |
Why?
|
| Immunohistochemistry | 2 | 2016 | 928 | 0.070 |
Why?
|
| Culture | 1 | 2007 | 172 | 0.060 |
Why?
|
| Social Change | 1 | 2006 | 19 | 0.060 |
Why?
|
| State Government | 1 | 2006 | 21 | 0.060 |
Why?
|
| Vaccination | 2 | 2021 | 332 | 0.060 |
Why?
|
| CD4 Lymphocyte Count | 1 | 2006 | 200 | 0.060 |
Why?
|
| Social Environment | 1 | 2007 | 218 | 0.060 |
Why?
|
| Research Support as Topic | 1 | 2006 | 89 | 0.060 |
Why?
|
| Infertility, Female | 1 | 2005 | 24 | 0.060 |
Why?
|
| DNA, Ribosomal | 1 | 2025 | 39 | 0.060 |
Why?
|
| Maternal Mortality | 1 | 2005 | 26 | 0.060 |
Why?
|
| Lactobacillus | 1 | 2025 | 22 | 0.060 |
Why?
|
| Medically Underserved Area | 1 | 2006 | 118 | 0.060 |
Why?
|
| Pregnancy Outcome | 1 | 2005 | 92 | 0.060 |
Why?
|
| Prenatal Care | 1 | 2005 | 82 | 0.060 |
Why?
|
| RNA, Ribosomal, 16S | 1 | 2025 | 190 | 0.060 |
Why?
|
| DNA, Bacterial | 1 | 2025 | 207 | 0.050 |
Why?
|
| Interviews as Topic | 2 | 2018 | 428 | 0.050 |
Why?
|
| Pregnancy Complications | 1 | 2005 | 134 | 0.050 |
Why?
|
| Feeding Behavior | 1 | 2007 | 461 | 0.050 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2005 | 209 | 0.050 |
Why?
|
| Sequence Analysis, DNA | 1 | 2025 | 508 | 0.050 |
Why?
|
| Public Health | 1 | 2007 | 405 | 0.050 |
Why?
|
| Sociology, Medical | 1 | 2003 | 7 | 0.050 |
Why?
|
| Perforin | 1 | 2002 | 11 | 0.050 |
Why?
|
| Pore Forming Cytotoxic Proteins | 1 | 2002 | 6 | 0.050 |
Why?
|
| Antigens, CD19 | 1 | 2002 | 15 | 0.050 |
Why?
|
| Lymphocyte Subsets | 1 | 2002 | 21 | 0.050 |
Why?
|
| Immunophenotyping | 1 | 2002 | 57 | 0.050 |
Why?
|
| Receptors, Interleukin-2 | 1 | 2002 | 32 | 0.050 |
Why?
|
| Reproductive History | 1 | 2023 | 27 | 0.050 |
Why?
|
| Receptors, IgG | 1 | 2002 | 53 | 0.050 |
Why?
|
| Parity | 1 | 2023 | 60 | 0.050 |
Why?
|
| Bibliometrics | 1 | 2022 | 15 | 0.050 |
Why?
|
| Qualitative Research | 2 | 2018 | 526 | 0.050 |
Why?
|
| Capacity Building | 1 | 2023 | 99 | 0.050 |
Why?
|
| Quality of Health Care | 1 | 2023 | 158 | 0.050 |
Why?
|
| Fatal Outcome | 1 | 2002 | 46 | 0.050 |
Why?
|
| Tumor Virus Infections | 1 | 2002 | 22 | 0.050 |
Why?
|
| Mammography | 2 | 2019 | 211 | 0.050 |
Why?
|
| Health Services Research | 1 | 2003 | 161 | 0.050 |
Why?
|
| Cause of Death | 1 | 2022 | 183 | 0.050 |
Why?
|
| Anti-HIV Agents | 1 | 2006 | 475 | 0.050 |
Why?
|
| Interleukin-2 | 1 | 2002 | 90 | 0.050 |
Why?
|
| B-Lymphocytes | 1 | 2002 | 183 | 0.050 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2002 | 181 | 0.040 |
Why?
|
| Cancer Care Facilities | 1 | 2021 | 19 | 0.040 |
Why?
|
| Exercise | 1 | 2007 | 674 | 0.040 |
Why?
|
| Cell Division | 1 | 2002 | 314 | 0.040 |
Why?
|
| Membrane Glycoproteins | 1 | 2002 | 221 | 0.040 |
Why?
|
| Mortality | 1 | 2022 | 174 | 0.040 |
Why?
|
| Tumor Cells, Cultured | 1 | 2002 | 506 | 0.040 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2002 | 276 | 0.040 |
Why?
|
| Research | 1 | 2022 | 177 | 0.040 |
Why?
|
| Antibodies, Monoclonal | 1 | 2002 | 301 | 0.040 |
Why?
|
| Delayed Diagnosis | 1 | 2020 | 33 | 0.040 |
Why?
|
| Family | 1 | 2021 | 192 | 0.040 |
Why?
|
| Smoking | 1 | 2006 | 1019 | 0.040 |
Why?
|
| Regression Analysis | 1 | 2020 | 487 | 0.040 |
Why?
|
| Chemoprevention | 1 | 2019 | 41 | 0.040 |
Why?
|
| Cytokines | 1 | 2002 | 661 | 0.040 |
Why?
|
| Time Factors | 1 | 2002 | 1848 | 0.030 |
Why?
|
| Electronic Health Records | 1 | 2019 | 99 | 0.030 |
Why?
|
| Population Groups | 1 | 2017 | 59 | 0.030 |
Why?
|
| Pilot Projects | 1 | 2019 | 733 | 0.030 |
Why?
|
| Clinical Protocols | 1 | 2016 | 36 | 0.030 |
Why?
|
| Child, Preschool | 1 | 2021 | 1516 | 0.030 |
Why?
|
| Odds Ratio | 1 | 2017 | 587 | 0.030 |
Why?
|
| Electrophoresis, Gel, Two-Dimensional | 1 | 2016 | 78 | 0.030 |
Why?
|
| Health Education | 2 | 2012 | 358 | 0.030 |
Why?
|
| Colorimetry | 1 | 2016 | 52 | 0.030 |
Why?
|
| Cameroon | 1 | 2015 | 35 | 0.030 |
Why?
|
| Reproducibility of Results | 1 | 2019 | 1058 | 0.030 |
Why?
|
| Marriage | 1 | 2013 | 18 | 0.030 |
Why?
|
| Antineoplastic Agents | 1 | 2002 | 979 | 0.030 |
Why?
|
| Blotting, Western | 1 | 2016 | 884 | 0.030 |
Why?
|
| Models, Theoretical | 1 | 2015 | 230 | 0.030 |
Why?
|
| DNA, Viral | 1 | 2015 | 323 | 0.030 |
Why?
|
| Counseling | 1 | 2013 | 134 | 0.020 |
Why?
|
| Vaginosis, Bacterial | 1 | 2012 | 8 | 0.020 |
Why?
|
| Government Programs | 1 | 2012 | 29 | 0.020 |
Why?
|
| Preventive Medicine | 1 | 2011 | 16 | 0.020 |
Why?
|
| Probiotics | 1 | 2012 | 37 | 0.020 |
Why?
|
| Risk | 1 | 2011 | 289 | 0.020 |
Why?
|
| Bacteria | 1 | 2012 | 285 | 0.020 |
Why?
|
| Social Support | 1 | 2012 | 438 | 0.020 |
Why?
|
| Motivation | 1 | 2012 | 492 | 0.020 |
Why?
|
| Carcinoma, Adenosquamous | 1 | 2006 | 5 | 0.020 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 2006 | 17 | 0.020 |
Why?
|
| Cotinine | 1 | 2006 | 44 | 0.020 |
Why?
|
| Combined Modality Therapy | 1 | 2006 | 174 | 0.020 |
Why?
|
| Health Priorities | 1 | 2006 | 25 | 0.020 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2005 | 23 | 0.020 |
Why?
|
| Infusions, Intravenous | 1 | 2005 | 55 | 0.020 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2005 | 53 | 0.010 |
Why?
|
| Fluorouracil | 1 | 2005 | 46 | 0.010 |
Why?
|
| Drug Administration Schedule | 1 | 2005 | 153 | 0.010 |
Why?
|
| Cisplatin | 1 | 2005 | 91 | 0.010 |
Why?
|
| Neoplasm Metastasis | 1 | 2006 | 233 | 0.010 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2006 | 187 | 0.010 |
Why?
|